Kepler Capital analyst David Cerdan maintained a Hold rating on Koninklijke Philips (NYSE:PHG) N.V. on Tuesday, setting a price target of EUR34, which is approximately 21.39% below the present share price of $43.25.
Cerdan expects Koninklijke Philips N.V. to post earnings per share (EPS) of $0.00 for the second quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Koninklijke Philips, with an average price target of $38.84.
The analysts price targets range from a high of $40.49 to a low of $37.2.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $4.16 billion and a net profit of $43 million. The company's market cap is $38.57 billion.
According to TipRanks.com, Kepler Capital analyst David Cerdan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.8% and a 33.91% success rate.
Royal Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Personal Health, Diagnosis & Treatment, Connected Care & Health Informatics, and Other. The Personal Health segment focuses on healthy living and preventative care. This segment comprises the Personal Care, Domestic Appliances, Oral Healthcare, and Mother & Child Care businesses. The Diagnosis & Treatment segment unites the businesses related to the promise of precision diagnosis and disease pathway selection, and the businesses related to image-guided, minimally invasive treatments. This segment comprises the Diagnostic Imaging, Ultrasound, Healthcare Informatics and Image-Guided Therapy businesses. The Connected Care & Health Informatics segment focuses on patient care solutions, advanced analytics and patient and workflow optimization inside and outside the hospital, and aims to unlock synergies from integrating and optimizing patient care pathways and leveraging provider-payer-patient business models. This segment comprises the Monitoring & Analytics, Therapeutic Care, Population Health Management, and Sleep & Respiratory Care businesses. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.